五个在美国准备上市的肺癌新药.

5 Lung Cancer Drugs To Be Launched By 2014

Xalkori (Crizotinib)
Xalkori received a fast track approval in its phase II trial. The drug has been launched in August 2011 and is being reviewed by the European Medical Agency. This is a prescription drug used for treating non-small cell lung cancer (NSCLC) that is in its advanced stages and is caused due to a mutation in the anaplastic lymphoma kinase (ALK) gene.

Afatinib
Afatinib is a next generation inhibitor of epidermal growth factor receptor (EGFR) and human epidermal receptor 2(HER2) tyrosine kinase. The compound is being developed in several solid tumor types. Phase III trials of the drug has seen promising results.

Dacomitinib
Dacomitinib is an oral irreversible inhibitor of HER1, HER2, and HER4 tyrosine kinases developed at Pfizer. In Phase III study (ARCHER 1009); Pfizer plans to evaluate dacomitinib’s efficacy and safety in comparison to Tarceva in the study population.

Talactoferrin
Talactoferrin is a genetically engineered form of human protein lactoferrin. Lactoferrin is found in body secretions like breast milk, saliva, and tears. Clinical trials have proved that talactoferrin improves survival in patients with NSCLC without toxic side effects. DSM and AGENNIX have signed up for commercial manufacture of Talactoferrin.

ARQ 197
ARQ 197 is a small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with NSCLC. ArQule, Inc. and Daiichi Sankyo Co., Ltd. have moved ARQ197 into Phase III clinical trials. The trial would compare efficacy of ARQ197 and Erlotinib against Erlotinib and placebo.

安德森医生说特罗凯耐药后, Dacomitinib比Afatinib可能会更好,因为Afatinib是同EGFR靶点.

吉利牛 发表于 2013-3-5 23:16

                               
登录/注册后可看大图

安德森医生说特罗凯耐药后, Dacomitinib比Afatinib可能会更好,因为Afatinib是同EGFR靶点.

Dacomitinib是HER1, HER2, and HER4
不是一个靶点，能比较么？

标注，学习ing

知难而进 发表于 2013-3-5 23:21

                               
登录/注册后可看大图

Dacomitinib是HER1, HER2, and HER4
不是一个靶点，能比较么？

那要看耐药后的癌细胞. 最好有的放矢. 盲试也可以. 我有认识的美国病友,特耐药后医生给用Afatinib,估计耐药还不太厉害,但太严重,如再次转移了, 医生就先上化疗,分析活检后, 给用Dacomitinib. ,我也没彻底明白. 这些药现在都是临床,快上市了.

ARQ 197也值得关注. 特耐药后,可能有25% CMET突变.

吉利牛 发表于 2013-3-6 00:08

                               
登录/注册后可看大图

那要看耐药后的癌细胞. 最好有的放矢. 盲试也可以. 我有认识的美国病友,特耐药后医生给用Afatinib,估计耐 ...

嗯，我感觉国内大多都是盲试，尤其耐药以后，根本没听说过再去测免疫组化的。

我妈的医生更是有趣，特罗凯耐药后就直接化疗化疗后又让继续吃特罗凯，好像这世界上就只有特罗凯一种靶向药似的。

老马叔~您是说克唑替尼已经上市了，但我看论坛里吃克的朋友们都还是在镜湖医院开的？是因为虽然上市但未进入中国吗？另外，省医那边现在ALK的试验组还在开放，测试的应该就是克药。。。那是不是说起码还有一段时间内克要是不会在中国上？至少要等试验组测试通过后才能上？

学习！谢谢！老马的注解

不管怎么样，都让我看到了希望，大家加油啊！